Jupiter Neurosciences Raises $2 Million in Registered Direct Offering

Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, has closed a securities purchase agreement for the sale of 7,142,858 shares of common stock in a registered direct offering. The offering generated gross proceeds of approximately $2.0 million, according to a press release.

D. Boral Capital LLC acted as the exclusive placement agent for the offering, which was conducted under the company’s effective shelf registration statement on Form S-3, declared effective by the U.S. Securities and Exchange Commission on April 24, 2026. The company’s ability to raise capital through this structure provides flexibility to fund ongoing research and development activities.

The proceeds are expected to support Jupiter’s lead program, JOTROL™, a proprietary enhanced bioavailability resveratrol formulation currently in a Phase IIa clinical trial for Parkinson’s disease. Parkinson’s affects millions worldwide, and there is a significant unmet need for disease-modifying therapies. JOTROL’s ability to cross the blood-brain barrier and reduce neuroinflammation could position it as a potential treatment option if clinical trials succeed.

Additionally, Jupiter commercializes Nugevia™, a consumer longevity supplement, and recently acquired the U.S. rights to ALA-002, a next-generation patented psychedelic new chemical entity. The acquisition of ALA-002 strengthens the company’s CNS pipeline at a pivotal moment in U.S. regulatory policy, as psychedelic-assisted therapies gain attention for conditions like depression and post-traumatic stress disorder.

The closing of this offering is important for Jupiter as it provides necessary capital to advance its pipeline without immediate dilution from debt financing. For investors, the offering signals confidence from placement agent D. Boral Capital and the market in Jupiter’s strategy. The company’s focus on neuroinflammation—a common pathway in many CNS disorders—could yield broad therapeutic applications if JOTROL and other candidates prove effective.

More details on the offering can be found in the full press release at https://ibn.fm/o5A0w. Jupiter Neurosciences continues to trade on NASDAQ under the symbol JUNS, and additional information is available at www.jupiterneurosciences.com.

The implications of this capital raise extend beyond Jupiter. It reflects a broader trend in biotech financing where registered direct offerings allow companies to secure funding efficiently. For the CNS space, which has historically faced high failure rates, access to capital is critical for advancing novel therapies. Jupiter’s progress with JOTROL and ALA-002 could contribute to addressing the growing burden of neurodegenerative and psychiatric disorders.